Mercados españoles cerrados

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
120,42-0,09 (-0,07%)
Al cierre: 04:00PM EDT
120,00 -0,42 (-0,35%)
Después del cierre: 06:39PM EDT

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road
Dublin D04 E5W7
Ireland
353 1 634 7800
https://www.jazzpharma.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo2800

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Bruce C. CozaddCo-Founder, Chairman & CEO2,45M13,66M1964
Ms. Reneé D. GaláPresident & COO1,13MN/A1972
Mr. Daniel N. Swisher Jr.Non-Executive Employee1,47MN/A1963
Dr. Robert Iannone M.D.Executive VP and Global Head of Research & Development1,08MN/A1967
Mr. Philip L. JohnsonExecutive VP & CFON/AN/AN/A
Ms. Patricia CarrSenior VP & Chief Accounting OfficerN/AN/A1972
Ms. Andrea N. Flynn Ph.D.VP & Head of Investor RelationsN/AN/AN/A
Ms. Neena M. Patil J.D.Executive VP & Chief Legal Officer331,61kN/A1976
Dr. George Christopher Eliades Ph.D.Senior VP of Corporate Development & Chief Transformation OfficerN/AN/A1971
Ms. Heidi MannaExecutive VP & Chief People OfficerN/AN/A1972
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Gobierno corporativo

El ISS Governance QualityScore de Jazz Pharmaceuticals plc, a día 1 de marzo de 2024, es 3. Las puntuaciones base son Auditoría: 6; Tablero: 3; Derechos de los accionistas: 3; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.